Biocon Biologics completes acquisition of Viatris biosimilars biz for $3.3 bn

/2 min read

ADVERTISEMENT

Biocon Biologics, Viatris get all key approvals from global regulators, including US FTC, CCI, RBI, and investors. Biocon Ltd’s stake in Biocon Biologics to rise to 68%.
Biocon Biologics completes acquisition of Viatris biosimilars biz for $3.3 bn
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Biologics 

The shares of biopharmaceutical company Biocon Ltd surged a day after the successful completion of its subsidiary Biocon Biologics’ $3.34 billion acquisition of the global biosimilars business of US-based healthcare firm Viatris Inc. The stock opened a gap-up at ₹284.2 and rose to an intra-day high of ₹286.95, before settling at ₹282.10 on the BSE. The Biocon Ltd share closed 0.30% up at ₹282.95.

The Kiran Mazumdar-Shaw-led company's acquisition deal comprises an upfront cash payment of $2 billion and the issuance of compulsorily convertible preference shares (CCPS) in Biocon Biologics worth $1 billion. It is equivalent to an equity stake of at least 12.9% on a fully diluted basis.

The company, in an exchange filing, said both Biocon Biologics and Viatris have obtained all applicable approvals from key global regulators, including the US Federal Trade Commission, the Competition Commission of India and the Reserve Bank of India, and its investors.

Fortune India Latest Edition is Out Now!
40u40: India's Brightest Young Business Minds

July 2025

In the world’s youngest nation—where over 65% of the population is under 35—India’s future is already being shaped by those bold enough to lead it. From boardrooms to breakout ideas, a new generation of business leaders is rewriting the rules. This year's Fortune India’s 40 Under 40 celebrates these changemakers—icons in the making like Akash Ambani, Kaviya Kalanithi Maran, Shashwat Goenka, Parth Jindal, Aman Mehta, and Devansh Jain—who are not just carrying forward legacies but boldly reimagining them for a new era. Alongside them are first-generation disruptors like Sagar Daryani, scaling Wow! Momo with a vision to take ₹100 momos to 5,000 cities, and Palak Shah, turning the Banarasi weave into a global fashion story with Ekaya Banaras. These are the entrepreneurs turning ambition into scale. And even beyond traditional industry, the entrepreneurial wave is pulling in creative forces—Ranveer Singh, for instance, is shaking up wellness and nutrition with Bold Care and SuperYou, proving that passion, backed by purpose, is the new blueprint for building brands.

Read Now

"Effective from the date of closing, Biocon Biologics will recognise the combined revenue and associated profits from the acquired products, a step up from the existing profit share arrangement," said Biocon.

To fund the deal, Biocon Biologics secured $1.2 billion of Sustainability Linked Loan (SLL) via an equity infusion of $650 million by Biocon Limited and $150 million by vaccine giant Serum Institute Life Sciences (SILS). Biocon Ltd’s funding comprises $230 million from existing reserves and $420 million through mezzanine financing. Biocon said it is also in the process of securing investments to retire the mezzanine financing, post-deal closure.

After the conclusion of the Viatris and Serum transactions, Biocon Ltd’s stake in Biocon Biologics will be 68%.

The company says the acquisition will place Biocon Biologics as a world-leading biosimilar player, with eight commercialised products. Now Biocon Biologics will have direct commercial capabilities and supporting infrastructure in the advanced markets and several emerging markets. "The integration of Viatris’ acquired global biosimilars business and Biocon Biologics’ existing capabilities in research and development, global scale manufacturing and commercialisation in several emerging markets positions Biocon Biologics as a unique, fully integrated, leading global biosimilars player."

Biocon Biologics will have full ownership of its collaboration assets -- bTrastuzumab, bPegfilgrastim, bBevacizumab, bGlargine, bAspart, bPertuzumab and bGlargine 300U. It'll also own Viatris’ rights for the in-licensed immunology products -- bAdalimumab and bEtanercept. Biocon Biologics has also acquired Viatris’ rights for bAflibercept, which is used to treat several ophthalmology conditions. Viatris has been the 'first to file' bAflibercept in the U.S.

Kiran Mazumdar-Shaw, the executive chairperson, Biocon Biologics, termed it a historic inflection point in Biocon's journey of becoming a world-leading, fully integrated biosimilars enterprise, which will fast-track its direct entry into several advanced and emerging markets.

Viatris has said it'll provide commercial and other transition services to Biocon Biologics for up to two years. Rajiv Malik, president of Viatris, has joined the board of directors of Biocon Biologics, effective November 29, 2022, while Kiran Mazumdar-Shaw will continue as the executive chairperson of Biocon Biologics Ltd.

Fortune India is now on WhatsApp! Get the latest updates from the world of business and economy delivered straight to your phone. Subscribe now.